Compare Citius Pharmaceuticals Inc (CTXR) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $30.7, down 7.05% in the last 24 hours, reflecting high volatility tied to its leveraged exposure to NVIDIA. Technical indicators show a bullish trend with moving averages supporting upward momentum, while oscillators remain neutral. Recent stock splits on June 25 and 26, 2026, adjusted the share structure, but key financial ratios like P/E and P/S are unavailable, limiting fundamental clarity. The ETF's performance is directly driven by daily NVIDIA price movements, amplified by its 2x leverage.

The outlook for NVDL hinges on NVIDIA's AI-driven growth, offering potential for high returns but with significant risk due to leverage compounding losses during downturns. Investors face volatility risks, as seen in a 12% single-day drop on June 5, 2026, and must monitor NVIDIA's earnings and broader semiconductor trends. Caution is advised given the lack of traditional fundamentals and the ETF's reset mechanism, which can erode value over time in volatile markets.